vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and HighPeak Energy, Inc. (HPK). Click either name above to swap in a different company.
HighPeak Energy, Inc. is the larger business by last-quarter revenue ($216.6M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -11.6%, a 25.0% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -23.3%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -13.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Duke Energy Corporation is an American electric power and natural gas holding company headquartered in Charlotte, North Carolina. The company serves over 7 million customers in the eastern United States. In 2024 it ranked as the 141st largest company in the United States – its highest-ever placement on the Fortune 500 list.
AMPH vs HPK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $216.6M |
| Net Profit | $24.4M | $-25.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -7.6% |
| Net Margin | 13.3% | -11.6% |
| Revenue YoY | -1.8% | -23.3% |
| Net Profit YoY | -35.7% | -380.7% |
| EPS (diluted) | $0.51 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $216.6M | ||
| Q3 25 | $191.8M | $188.9M | ||
| Q2 25 | $174.4M | $200.4M | ||
| Q1 25 | $170.5M | $257.4M | ||
| Q4 24 | $186.5M | $282.6M | ||
| Q3 24 | $191.2M | $271.6M | ||
| Q2 24 | $182.4M | $275.3M | ||
| Q1 24 | $171.8M | $287.8M |
| Q4 25 | $24.4M | $-25.2M | ||
| Q3 25 | $17.4M | $-18.3M | ||
| Q2 25 | $31.0M | $26.2M | ||
| Q1 25 | $25.3M | $36.3M | ||
| Q4 24 | $38.0M | $9.0M | ||
| Q3 24 | $40.4M | $49.9M | ||
| Q2 24 | $37.9M | $29.7M | ||
| Q1 24 | $43.2M | $6.4M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -7.6% | ||
| Q3 25 | 13.2% | 17.3% | ||
| Q2 25 | 24.2% | 21.7% | ||
| Q1 25 | 21.9% | 35.1% | ||
| Q4 24 | 24.2% | 26.1% | ||
| Q3 24 | 29.8% | 27.0% | ||
| Q2 24 | 30.3% | 31.7% | ||
| Q1 24 | 27.9% | 35.8% |
| Q4 25 | 13.3% | -11.6% | ||
| Q3 25 | 9.0% | -9.7% | ||
| Q2 25 | 17.8% | 13.1% | ||
| Q1 25 | 14.8% | 14.1% | ||
| Q4 24 | 20.4% | 3.2% | ||
| Q3 24 | 21.1% | 18.4% | ||
| Q2 24 | 20.8% | 10.8% | ||
| Q1 24 | 25.1% | 2.2% |
| Q4 25 | $0.51 | $-0.16 | ||
| Q3 25 | $0.37 | $-0.15 | ||
| Q2 25 | $0.64 | $0.19 | ||
| Q1 25 | $0.51 | $0.26 | ||
| Q4 24 | $0.74 | $0.06 | ||
| Q3 24 | $0.78 | $0.35 | ||
| Q2 24 | $0.73 | $0.21 | ||
| Q1 24 | $0.81 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $162.1M |
| Total DebtLower is stronger | $608.7M | $1.2B |
| Stockholders' EquityBook value | $788.8M | $1.6B |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | 0.77× | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $162.1M | ||
| Q3 25 | $276.2M | $164.9M | ||
| Q2 25 | $231.8M | $21.9M | ||
| Q1 25 | $236.9M | $51.6M | ||
| Q4 24 | $221.6M | $86.6M | ||
| Q3 24 | $250.5M | $135.6M | ||
| Q2 24 | $217.8M | $157.9M | ||
| Q1 24 | $289.6M | $173.4M |
| Q4 25 | $608.7M | $1.2B | ||
| Q3 25 | $608.6M | $1.2B | ||
| Q2 25 | $607.7M | $1.0B | ||
| Q1 25 | $603.9M | $1.0B | ||
| Q4 24 | $601.6M | $1.0B | ||
| Q3 24 | $596.4M | $1.1B | ||
| Q2 24 | $586.9M | $1.1B | ||
| Q1 24 | $594.0M | $1.1B |
| Q4 25 | $788.8M | $1.6B | ||
| Q3 25 | $776.7M | $1.6B | ||
| Q2 25 | $757.5M | $1.7B | ||
| Q1 25 | $751.3M | $1.6B | ||
| Q4 24 | $732.3M | $1.6B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.6B | ||
| Q1 24 | $672.4M | $1.5B |
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.7B | $3.2B | ||
| Q2 25 | $1.6B | $3.1B | ||
| Q1 25 | $1.6B | $3.1B | ||
| Q4 24 | $1.6B | $3.1B | ||
| Q3 24 | $1.5B | $3.1B | ||
| Q2 24 | $1.5B | $3.1B | ||
| Q1 24 | $1.6B | $3.1B |
| Q4 25 | 0.77× | 0.75× | ||
| Q3 25 | 0.78× | 0.73× | ||
| Q2 25 | 0.80× | 0.62× | ||
| Q1 25 | 0.80× | 0.63× | ||
| Q4 24 | 0.82× | 0.65× | ||
| Q3 24 | 0.82× | 0.67× | ||
| Q2 24 | 0.82× | 0.70× | ||
| Q1 24 | 0.88× | 0.73× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $93.1M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $93.1M | ||
| Q3 25 | $52.6M | $120.2M | ||
| Q2 25 | $35.6M | $141.2M | ||
| Q1 25 | $35.1M | $157.1M | ||
| Q4 24 | $29.0M | $139.5M | ||
| Q3 24 | $60.0M | $177.1M | ||
| Q2 24 | $69.1M | $202.3M | ||
| Q1 24 | $55.3M | $171.4M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | — | ||
| Q2 25 | $25.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | — | ||
| Q2 24 | $63.1M | — | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.3% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | — | ||
| Q2 24 | 34.6% | — | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 6.3% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 5.1% | — |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 5.39× | ||
| Q1 25 | 1.39× | 4.32× | ||
| Q4 24 | 0.76× | 15.53× | ||
| Q3 24 | 1.48× | 3.55× | ||
| Q2 24 | 1.82× | 6.81× | ||
| Q1 24 | 1.28× | 26.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
HPK
| Crude Oil Sales | $152.1M | 70% |
| Natural Gas And NGL Sales | $60.8M | 28% |
